The effect of melatonin on tinnitus with respect to sleep and depression : a randomized clinical trial
Yükleniyor...
Dosyalar
Tarih
2012
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Aves
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: In this study we aimed to investigate the psychological status of tinnitus patients as well as the sleep quality and their relation to handicap caused by tinnitus using various scales. Additionally, serum melatonin levels and the effectiveness of melatonin treatment were studied. Study Design: Prospective, double blind, randomized controlled trial Materials and Methods: Patients were divided randomly into two groups as study (melatonin, n=13) and placebo (control, n=11) groups. Tinnitus Handicap Inventory (THI), Symptom Check List (SCL), Hospital Anxiety and Depression Scale (HAD), Beck Depression Inventory (BDI), Pittsburg Sleep Qualty Index (PSQI) were applied. After filling the scales and giving the venous blood sample for melatonin measurements the patients were instructed to take one tablet (placebo or 3 mg melatonin) before sleep every night. After 8 weeks, second order scales were filled and melatonin measurements were repeated. Results: Serum melatonin levels were between 1-260 pg/ml; the mean was 38,7 pg/ml. The correlation of melatonin levels with THI and tinnitus duration was not significant. THI was found to correlate with different measures of the PSQI, HAD, and BDI in both groups. Statistical analysis failed to show any significant difference within and between groups in respect of anxiety, depressive symptoms and sleep as well as melatonin and handicap levels. When the groups were assessed according to the THI severity (mild/moderate to severe;THI2); in the control group there was significant differences in PSQI(1) and PSQI(1) (p=0.0008, p=0.18), NAD(1), HAD(2) (0.002, 0.03), HAD Depression(1-2) (0.0, 0.006) BDI (p=0.007) PSQI(2 sleep) (disturbance) (P=0.018) parameters. However, in the melatonin group it was found that there were significant differences in SCL2 (sleep) (latency), PSQI(2) (sleep) (duration) and total PSQI(2) parameters. (p=0.022, 0.027, 0.006 respectively) Conclusion: Patients with higher handicap may benefit melatonin in respect of sleep latency and duration as well as sleep quality comparing with the patients taking placebo. Moreover, melatonin efficiency may be related to its antidepressive effect.
Açıklama
Anahtar Kelimeler
Kaynak
Journal Of International Advanced Otology
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
8
Sayı
2
